Plasminogen, Fibrinogen, α₂-Antiplasmin And Antithrombintii Levels During A Single Cycle of a Comined • Oral Contraceptive Regime

References

• Inmann WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the committee on safety of drugs. Br Med J. 1970; 2: 203–9.
   Google Scholar
• Editorial. Oral contraceptives: mechanisms in thromboembolism. Lancet. 1980; 1: 1118–9.
   Google Scholar
• Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet. 1980; 1: 1097–101
   Google Scholar
• Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of piasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis. 1978; 7:138–45
   Google Scholar
• Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid piasmin inhibitor in human blood by means of a piasmin specific tripeptide substrate. Scand J Clin Lab Invest. 1977; 37: 402–9.
   Google Scholar
• Odegard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res. 1975; 6: 287–94.
   Google Scholar
• Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with « new » chromogenic substrates (S-2238 and chromozym-TH). Thromb Res. 1977; 11:549–53.
   Google Scholar
• Vermylen C, Verstraete M, Devreker RA. A simple method for the instantaneous quantitation of fibrinogen: the FPT test. Acta Clin Belg. 1963; 18: 200–7.
   Google Scholar
• Vessey MP, Weatherall JAC. Venous thromboembolic disease and the use of oral contraceptives. Lancet. 1968; 2: 94–6.
   Google Scholar
• Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and throm boembolic disease. A further report. Brit Med J. 1969; 2: 651–7.
   Google Scholar
• Dugdale M, Masi AT. Hormonal contraception and thromboembolic disease: effects of the oral contracepties on hemostatic mechanisms. A review of the literature. J Chron Dis. 1971;23:775–90.
   Google Scholar
• Ffigerhol MK, Abildgaard U. Immunological studies on human antithrombin-III. Influence of age, sex and use of oral contraceptives on serum concentration. Scand J Haemal. 1970; 7: 10–7.
   Google Scholar
• Howie PW, Mallinson AC, Prentice CRM, Home CHW, McNicol GP. Effect of combi ned oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity. Lancet. 1970; 2: 1329–32.
   Google Scholar
• Von Kaulla E, Droegemueller W, Aoki N, Von Kaulla KN. Antithrombin III depression and thrombin generation acceleration in women taking oral contraceptives. Am J Obstet Gynec. 1971; 109: 868–73.
   Google Scholar
• Zuck TF, Bergin JJ, Raymond JM, Dwyre WR. Implications of depressed antithrombinIII activity associated with oral contraceptives. Surg Gynecol Obstet. 1971; 133: 609–12.
   Google Scholar
• Larsson-Cohn U, Fagerhol MK, Abildgaard U. Concentration of antithrombin-III during combined and progestogen-only oral contraceptive treatment. Acta Obstet Gynec Scand. 1972; 51: 315–7.
   Google Scholar
• Conard J. Salomon Y, Samama M. Variations de I’antithrombine III chez les femmes sous contraception orale. Path Biol. 1974; 22: 7788.
   Google Scholar
• Conard J, Cazenave B, Samama M, HorelVe Mil, Zorn JR, Neau C. AT III content and antithrombin activity in oestrogenprogestogen and progestogen only treated women. Thromb Res. 1980: 18: 675–81.
   Google Scholar
• Hedlin AM. The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis. Thromb Diath Haemorrh. 1975; 33: 3/08.
   Google Scholar
• Sagar S, Stamatakis JD, Thomas DP, Kakkar VV. Oral contraceptives, antithrombin-III activity and postoperative deep-vein thrombosis. Lancet. 1976; 1: 509–11.
   Google Scholar
• Ball AP, McKee PA. Fibrin formation and dissolution in women receiving oral contraceptive druKS. J Lab Clin Med. 1977; 89: 75 l-o2.
   Google Scholar
• Brakman P, Astrup T. Effects of female hormones, used as oral contraceptives, on the fibrinolytic system in blood. Lancet. 1964; 2: 102.
   Google Scholar
• Medhat IA, Toppozada HK, Rizk MA, Khowessah MM, Malek ATA, Moghazi M. A study of the effect of an oral contraceptive on blood coagulation factors, platelets and fibrinolytic activity. Contraception. 1974; 9: 37992.
   Google Scholar
• Meade TW, Brozovic M, Chakrabarti R, Howarth DJ, North WRS, Stirling Y. An epidemiological study of haemostatic and other effects of oral contraceptives. Brit J Haemal. 1979; 34: 353 64.
   Google Scholar
• Ambrus JL, Niswander RR, Courey NG, Wamsteker EF, Mink IB. Progestational agents and blood coagulation 11. Am J Obstet Gynecol. 1969; 103: 994–1001.
   Google Scholar
• Menon IS, Peberdy M, Rannie GH, Weighiman D, Dewar HA. A comparative study of blood fibrinolytic activity in normal women, pregnant women and women on oral contra ceplives. Obstet Gynaec Br Commonw. 1970; 77: 752–6.
   Google Scholar
• Ygge J, Brody S, Korsan-Bengsten K, Nilsson L. Changes in blood coagulation and fibrinolysis in women receiving oral contraceptives. Am J Obstet Gynecol. 1969; 104: 87–98.
   Google Scholar
• Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976; 69: 20–16.
   Google Scholar
• Collen D, Wiman B. Fast-acting plasmin inhibitor in human plasma. Blood. 1978; 51: 563
   Google Scholar
• Moroi M, Aoki N. Isolation and characterization of a,-plasmin inhibitor from human plasma. Biol Chem. 1976; 251: 5856–65.
   Google Scholar
• Müllertz S. Different molecular forms of plasminogen and plasmin produced by Urokinasein human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin. Biochem J. 1974; 143: 273–83.
   Google Scholar
• Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976; 159: 545–53.
   Google Scholar
• Teger Nilsson A C. Use of chromogenic substrates for screening of inhibitors of coagulation and fibrinolysis in patients. In: « Chromogenic peptide substrates. Chemistry and clinical usage». (Scully MF, Kakkar VV, eds) Churchill Livingstone, Edinburgh London, and New York 1979; 269–76.
   Google Scholar
• Nilson IM, Kullander S. Coagulation and fibrinolytic studies during use of gestagens. Acta Obstet Gvnec Scand. 1967; 46: 286 303.
   Google Scholar
• Brakman P, Sobrero AJ, Astrup T. Effects of different systemic contraceptives on blood fibrinolysis. Am J Obstet Gynecol. 1970; 106 187–92.
   Google Scholar